ZymeLink™ Hemiasterlin

Hemiasterlin Drug-Linker

An alternative microtubule inhibitor with emerging utility as an ADC payload.

ZymeLink™ Hemiasterlin payload employs an N-acylsulfonamide spacer to enable linker cleavage, is specifically designed for antibody-drug conjugate (ADC) application, and is compatible with both cysteine and lysine conjugation.  The limited hydrophobicity of Zymelink Hemiasterlin drug linkers provides ADCs with improved pharmacokinetics, stability, and cytotoxin exposure over alternative ADC technologies. Hemiasterlins elicit cell death by binding to microtubules and inhibiting their assembly.

How It Works

ZymeLink™ Hemiasterlin uses traceless cleavable dipeptide linkers for antibody conjugation and is sufficiently hydrophilic to enable a DAR up to 8. Catabolism of the ADC following target engagement, internalization, and lysosomal trafficking releases the potent bystander active microtubule inhibitor ZD01886.



How We Differ

ZymeLink™ Hemiasterlin ADCs are designed to closely resemble natural antibodies with favorable pharmacokinetics, stability, limited deconjugation and premature release of payload in circulation to maximize payload exposure at the site of action.